Figure 6.

In vivo treatment experiments comparing subcutaneous vaccination and intratumoral vaccination. (A) Kaplan-Meier graph depicting the survival of TC-1 tumor bearing mice treated either intratumorally or subcutaneously with the combination of E7 and PADRE peptide with poly(I:C). The TC-1 tumor-bearing C57BL/6 mice (5 per group) were immunized either subcutaneously or intratumorally using the combination of 20 μg/mouse of HPV-16 E7 (aa 49-57) peptide and 20 μg/mouse of PADRE peptide with 20 μg/mouse of poly(I:C). The mice were given one booster with the same peptide regimen and dose every week at the same site until they died or the tumor reaches 2 cm in diameter and survival was analyzed by Kaplan & Meier analysis. (B) Kaplan-Meier graph depicting survival of TC-1 tumor bearing mice treated intratumorally with the various combinations of reagents. Tumor-bearing C57BL/6 mice (5 per group) were treated via intratumoral injection using 20 μg/mouse of HPV-16 E7 (aa 49-57) peptide with 20 μg/mouse of PADRE peptide or with 20 μg/mouse of poly(I:C) or with both poly(I:C) and PADRE peptide. Tumor-bearing mice treated with PBS or with poly(I:C) and PADRE without E7 peptide were used as controls. The mice were given booster with the same dose every 5 days at the same site until they died or the tumor reaches 2 cm in diameter and survival was analyzed by Kaplan & Meier analysis. Data shown are representative of two experiments performed.